Comparative Effectiveness and Cost-Effectiveness of Natalizumab and Fingolimod in Patients with Inadequate Response to Disease-Modifying Therapies in Relapsing-Remitting Multiple Sclerosis in the United Kingdom
| Image |  |
|---|---|
| Description | journal article from 'PharmacoEconomics' published in 2022 |
| Author/s | |
| Publication date | March 2022 |
| Language | English |
| Country of origin | |
| Wikipedia link | |
| Access work | |
| Copyright status | |
| Missing/wrong data? | Edit Wikidata item |